UK markets closed

Pfizer Inc. (PFE)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
40.02-0.08 (-0.20%)
At close: 4:02PM EDT

40.01 -0.01 (-0.02%)
After hours: 5:59PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close40.10
Open40.24
Bid39.98 x 2900
Ask40.06 x 1400
Day's range39.92 - 40.32
52-week range29.99 - 43.08
Volume13,500,046
Avg. volume30,302,112
Market cap223.238B
Beta (5Y monthly)0.67
PE ratio (TTM)20.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.56 (3.89%)
Ex-dividend date06 May 2021
1y target estN/A
All
News
  • Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
    Business Wire

    Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.

  • Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
    Business Wire

    Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Data to support the BLA will be submitted by the companies to the FDA on a rolling basis over the coming weeks, with a request for Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the agency.

  • Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
    Business Wire

    Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) to donate doses of the companies’ COVID-19 Vaccine to help vaccinate athletes, and their delegations, participating in the Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021.